StockNews.com started coverage on shares of bluebird bio (NASDAQ:BLUE – Free Report) in a report issued on Friday. The firm issued a sell rating on the biotechnology company’s stock. A number of other brokerages also recently weighed in on BLUE. Wells Fargo & Company reduced their price target on shares of bluebird bio from $60.00 […]

Equities research analysts at Chardan Capital initiated coverage on shares of Mind Medicine (MindMed) (NASDAQ:MNMD – Get Free Report) in a report released on Friday, MarketBeat.com reports. The firm set a “buy” rating and a $20.00 price target on the stock. Chardan Capital’s price objective would indicate a potential upside of 179.33% from the company’s […]